Medicine and Dentistry
Infection
100%
Pembrolizumab
100%
Clinical Oncology
66%
Overall Survival
41%
Immune Checkpoint Inhibitor
40%
Head and Neck Cancer
33%
Non Small Cell Lung Cancer
33%
Urothelial Cancer
33%
Small-Cell Carcinoma
33%
Therapeutic Modality
33%
Intensive Care Unit
22%
Emergency Department
22%
Odds Ratio
20%
Head and Neck Squamous Cell Carcinoma
19%
Electrocorticography
16%
Comorbidity
11%
Anti-Infective Therapy
8%
Cancer
8%
Progression Free Survival
7%
Retrospective Study
7%
Monotherapy
7%
Pelvis
5%
High Dose Chemotherapy
5%
Hypercalcaemia
5%
Fertility Preservation
5%
Diseases
5%
Cytoreductive Surgery
5%
Abdominal Swelling
5%
Long Term Survival
5%
Autologous Hematopoietic Stem Cell Transplantation
5%
Disease Free Survival
5%
Keyphrases
Impact on Patients
33%
Clinical Oncology
33%
Immune Checkpoint Inhibitors
33%
Pembrolizumab
33%
Head-and-neck Cancer
33%
Confidence Interval
26%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
26%
Few-cycle
20%
Overall Survival
20%
Chemotherapy
13%
Odds Ratio
13%
Infection Risk
13%
Anti-infective
13%
Inpatient Care Units
11%
Information Treatment
8%
Comorbidity
6%
Median Overall Survival
6%
Intensive Care Unit Admission
6%
Infectious Burden
6%
Treatment Cycle
6%
Kaplan-Meier Analysis
6%
Multivariable
6%
Cause of Death
6%
Impact Outcomes
6%
Chronic Infection
6%
Antitumor Activity
6%
Clinical Outcomes
6%
Monotherapy
6%
Intensive Care Unit
6%
Emergency Department Visits
6%
Line of Therapy
6%
Hospitalization
6%
Emergency Department Care
6%
Infected Patients
6%
Immunotherapy Benefits
6%
Adaptive Immune Response
6%
Fertility Preservation Surgery
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
100%
Infection
100%
Non Small Cell Lung Cancer
66%
Immune Checkpoint Inhibitor
47%
Head and Neck Cancer
33%
Overall Survival
32%
Head and Neck Squamous Cell Carcinoma
19%
Progression Free Survival
13%
Chemotherapy
12%
Retrospective Study
7%
Monotherapy
7%
Comorbidity
7%